Cancel
Will Sargent
Senior Vice President, Commercial Strategy
@
Venatorx Pharmaceuticals
76q72kz@55udj760.d0z
Sign up to see email
Known information
- Has over 25 years of biopharmaceutical industry experience.
- Led the launch and commercialization for Xenleta at Nabriva.
- Held leadership roles at Auxilium Pharmaceuticals, including Vice President, Orthopedic Business Unit.
- Worked as a biotechnology equities analyst at Bank of America.
- Held multiple commercial roles at Amgen and Immunex.
- Received a BA in Biology from Johns Hopkins University.
- Earned an MBA from the University of Washington Foster School of Business.
About Venatorx Pharmaceuticals
Venatorx Pharmaceuticals, founded in June 2010, focuses on developing novel anti-infectives to treat multi-drug-resistant bacterial and hard-to-treat viral infections. Their lead asset, cefepime-taniborbactam, has completed a Phase 3 study for complicated urinary tract infections and is under FDA review.
Report inaccurate information
